Search tips
Search criteria 


Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
J Exp Med. 1992 February 1; 175(2): 323–329.
PMCID: PMC2119112

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors


The receptors for tumor necrosis factor (TNF) exist in cell-associated as well as soluble forms, both binding specifically to TNF. Since the soluble forms of TNF receptors (sTNF-Rs) can compete with the cell- associated TNF receptors for TNF, it was suggested that they function as inhibitors of TNF activity; at high concentrations, the sTNF-Rs indeed inhibit TNF effects. However, we report here that in the presence of low concentrations of the sTNF-Rs, effects of TNF whose induction depend on prolonged treatment with this cytokine are augmented, reflecting an attenuation by the sTNF-Rs of spontaneous TNF activity decay. Evidence that this stabilization of TNF activity by the sTNF-Rs follows from stabilization of TNF structure within the complexes that TNF forms with the sTNF-Rs is presented here, suggesting that the sTNF-Rs can affect TNF activity not only by interfering with its binding to cells but also by stabilizing its structure and preserving its activity, thus augmenting some of its effects.

Full Text

The Full Text of this article is available as a PDF (597K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988;57:505–518. [PubMed]
  • Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y, Hadas E, Leitner O, Wallach D. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem. 1990 Aug 25;265(24):14497–14504. [PubMed]
  • Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, Adolf G. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol. 1989 Mar;42(3):270–275. [PubMed]
  • Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem. 1989 Jul 15;264(20):11966–11973. [PubMed]
  • Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989 Jul 15;264(20):11974–11980. [PubMed]
  • Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990 Jan 25;265(3):1531–1536. [PubMed]
  • Nophar Y, Kemper O, Brakebusch C, Englemann H, Zwang R, Aderka D, Holtmann H, Wallach D. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J. 1990 Oct;9(10):3269–3278. [PubMed]
  • Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem. 1987 May 25;262(15):6951–6954. [PubMed]
  • Narhi LO, Arakawa T. Dissociation of recombinant tumor necrosis factor-alpha studied by gel permeation chromatography. Biochem Biophys Res Commun. 1987 Sep 15;147(2):740–746. [PubMed]
  • Jones EY, Stuart DI, Walker NP. Structure of tumour necrosis factor. Nature. 1989 Mar 16;338(6212):225–228. [PubMed]
  • Eck MJ, Sprang SR. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem. 1989 Oct 15;264(29):17595–17605. [PubMed]
  • Israel S, Hahn T, Holtmann H, Wallach D. Binding of human TNF-alpha to high-affinity cell surface receptors: effect of IFN. Immunol Lett. 1986 Apr;12(4):217–224. [PubMed]
  • Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol. 1989 Dec 1;143(11):3517–3523. [PubMed]
  • Madsen M, Johnsen HE, Hansen PW, Christiansen SE. Isolation of human T and B lymphocytes by E-rosette gradient centrifugation. Characterization of the isolated subpopulations. J Immunol Methods. 1980;33(4):323–336. [PubMed]
  • Fischer DG, Hubbard WJ, Koren HS. Tumor cell killing by freshly isolated peripheral blood monocytes. Cell Immunol. 1981 Mar 1;58(2):426–435. [PubMed]
  • Wallach D. Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol. 1984 May;132(5):2464–2469. [PubMed]
  • Aderka D, Englemann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991 Oct 15;51(20):5602–5607. [PubMed]
  • Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988 Apr 30;1(8592):969–971. [PubMed]
  • Digel W, Stefanic M, Schöniger W, Buck C, Raghavachar A, Frickhofen N, Heimpel H, Porzsolt F. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood. 1989 Apr;73(5):1242–1246. [PubMed]
  • Vilcek J, Palombella VJ, Henriksen-DeStefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med. 1986 Mar 1;163(3):632–643. [PMC free article] [PubMed]
  • Petersen CM, Nykjaer A, Christiansen BS, Heickendorff L, Mogensen SC, Møller B. Bioactive human recombinant tumor necrosis factor-alpha: an unstable dimer? Eur J Immunol. 1989 Oct;19(10):1887–1894. [PubMed]
  • Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985 Dec;135(6):3972–3977. [PubMed]
  • Di Giovine FS, Nuki G, Duff GW. Tumour necrosis factor in synovial exudates. Ann Rheum Dis. 1988 Sep;47(9):768–772. [PMC free article] [PubMed]
  • Ophir D, Hahn T, Schattner A, Wallach D, Aviel A. Tumor necrosis factor in middle ear effusions. Arch Otolaryngol Head Neck Surg. 1988 Nov;114(11):1256–1258. [PubMed]
  • Waage A, Halstensen A, Shalaby R, Brandtzaeg P, Kierulf P, Espevik T. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J Exp Med. 1989 Dec 1;170(6):1859–1867. [PMC free article] [PubMed]
  • Møller B, Mogensen SC, Wendelboe P, Bendtzen K, Petersen CM. Bioactive and inactive forms of tumor necrosis factor-alpha in spinal fluid from patients with meningitis. J Infect Dis. 1991 Apr;163(4):886–889. [PubMed]
  • Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, Summer WR. Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis. 1989 Feb;159(2):189–194. [PubMed]
  • Johnson JD, Wong ML, Rutter WJ. Properties of the insulin receptor ectodomain. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7516–7520. [PubMed]
  • Greenfield C, Hiles I, Waterfield MD, Federwisch M, Wollmer A, Blundell TL, McDonald N. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J. 1989 Dec 20;8(13):4115–4123. [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press